{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:14:08Z","timestamp":1788502448743,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective is to evaluate the efficacy and safety of adding 1% topical cetirizine to 5% topical minoxidil compared with topical minoxidil alone in patients with androgenetic alopecia (AGA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In this single-blind randomized clinical trial, 62 patients with AGA were allocated to receive either topical minoxidil 5% twice daily (monotherapy group,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 31) or topical minoxidil 5% twice daily plus topical cetirizine 1% once daily (adjunctive therapy group,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 31) for 16 weeks. Primary outcomes included changes in hair density and hair diameter scores. Secondary outcomes were global photography score, patient satisfaction, and treatment-related adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>\n                      Both groups demonstrated improvement from baseline in hair density and hair diameter scores after 16 weeks of treatment. However, no significant differences were observed between groups in hair density score (0.65 \u00b1 0.61 vs. 0.68 \u00b1 0.60,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.987), hair diameter score (1.29 \u00b1 0.59 vs. 1.39 \u00b1 0.62,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.628), or global photography score (1.00 \u00b1 0.68 vs. 1.06 \u00b1 0.57,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.697). Patient satisfaction was significantly higher in the adjunctive therapy group than in the monotherapy group (1.82 \u00b1 1.07 vs. 1.13 \u00b1 0.85,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004). Two cases of local irritation were reported in the monotherapy group, whereas no adverse events were reported in the adjunctive therapy group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The addition of 1% topical cetirizine to topical minoxidil did not result in superior objective hair-growth outcomes compared with minoxidil alone. Although patient satisfaction was higher among patients receiving adjunctive cetirizine, this finding may be attributable to factors other than a direct pharmacologic effect. Further double-blind, vehicle-controlled studies with larger sample sizes are warranted to clarify the role of topical cetirizine in the management of AGA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_22_26","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:00:08Z","timestamp":1788501608000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Adding Topical Cetirizine to Minoxidil Therapy in Patients with Androgenetic Alopeci"],"prefix":"10.4103","volume":"15","author":[{"given":"Fatemeh","family":"Mokhtari","sequence":"first","affiliation":[{"name":"Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Faghihi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Maleki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Mohsen","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvane Sadeghi","family":"Dolatabadi","sequence":"additional","affiliation":[{"name":"Dr. Sadeghi Dolatabadi Pharmacy, Dr. Shariati Street, No. 181, Ground Floor, Shahid Bijan Vaezi Alley, Sichan District, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8]]},"reference":[{"key":"R1-20260904","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/ijd.ijd_729_23","article-title":"Androgenetic alopecia in men: An update on genetics","volume":"69","author":"Sadasivam","year":"2024","journal-title":"Indian J Dermatol"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF03401334","article-title":"The endocrinology of baldness","volume":"13","author":"Batrinos","year":"2014","journal-title":"Hormones (Athens)"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/ijt.ijt_6_19","article-title":"Quality of life assessment in patients with androgenetic alopecia","volume":"11","author":"Gupta","year":"2019","journal-title":"Int J Trichology"},{"key":"R4-20260904","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4103\/ijdvl.IJDVL_262_17","article-title":"Genetic and molecular aspects of androgenetic alopecia","volume":"84","author":"Martinez-Jacobo","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1111\/jocd.14537","article-title":"Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics","volume":"20","author":"Nestor","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/jdv.15171","article-title":"A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia","volume":"32","author":"Suchonwanit","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-20260904","first-page":"56","article-title":"Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): A systematic review","volume":"9","author":"Hirshburg","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JCP.0000000000001379","article-title":"Risk of depression associated with finasteride treatment","volume":"41","author":"Pompili","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.2147\/DDDT.S214907","article-title":"Minoxidil and its use in hair disorders: A review","volume":"13","author":"Suchonwanit","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/jrpp.JRPP_17_17","article-title":"Comparing the effects of zinc sulfate, calcium pantothenate, their combination and minoxidil solution regimens on controlling hair loss in women: A randomized controlled trial","volume":"6","author":"Siavash","year":"2017","journal-title":"J Res Pharm Pract"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40265-023-01880-x","article-title":"Androgenetic alopecia: Therapy update","volume":"83","author":"Devjani","year":"2023","journal-title":"Drugs"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/jocd.13714","article-title":"Microneedling in androgenetic alopecia: Comparing two different depths of microneedles","volume":"20","author":"Faghihi","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4103\/ijdvl.IJDVL_1156_16","article-title":"The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia","volume":"84","author":"Faghihi","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/jocd.15955","article-title":"Topical 5% minoxidil versus combined erbium YAG laser and topical 5% minoxidil in androgenetic alopecia: A randomized controlled trial","volume":"22","author":"Mokhtari","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"191","DOI":"10.18433\/jpps31456","article-title":"Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia: A randomized, single-blind controlled study","volume":"24","author":"Hossein Mostafa","year":"2021","journal-title":"J Pharm Pharm Sci"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jocd.13940","article-title":"Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case-controlled study","volume":"20","author":"Zaky","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/09546634.2017.1341610","article-title":"A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia","volume":"29","author":"Rossi","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0733-8635(05)70397-1","article-title":"Photographic documentation of hair growth in androgenetic alopecia","volume":"14","author":"Canfield","year":"1996","journal-title":"Dermatol Clin"},{"key":"R19-20260904","first-page":"1293","article-title":"Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: A randomized, double-blind, placebo-controlled study","volume":"315","author":"Bassiouny","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The alopecia areata investigator global assessment scale: A measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"126ra34","DOI":"10.1126\/scitranslmed.3003122","article-title":"Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia","volume":"4","author":"Garza","year":"2012","journal-title":"Sci Transl Med"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jep.2015.10.005","article-title":"In silico prediction of prostaglandin D2 synthase inhibitors from herbal constituents for the treatment of hair loss","volume":"175","author":"Fong","year":"2015","journal-title":"J Ethnopharmacol"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_22_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:00:11Z","timestamp":1788501611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_22_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_22_26","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-02-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}